1 Multi-organ genetic causal connections inferred from imaging and clinical data through

- 2 Mendelian randomization
- 3

4 Running title: MR atlas for multi-organ images

- 5
- 6 Juan Shu¹, Rong Zheng², Carlos Copana¹, Bingxuan Li³, Zirui Fan^{1,4}, Xiaochen Yang¹, Yilin Yang⁵,
- 7 Xiyao Wang³, Yujue Li¹, Bowei Xi¹, Tengfei Li^{6,7}, Hongtu Zhu^{8,9,10,11}*, and Bingxin Zhao^{1,4}*
- 8
- ⁹ ¹Department of Statistics, Purdue University, West Lafayette, IN 47907, USA.
- 10 ²Department of Ultrasound Imaging, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001,
- 11 China.
- 12 ³Department of Computer Science, Purdue University, West Lafayette, IN 47907, USA.
- ⁴Department of Statistics and Data Science, University of Pennsylvania, Philadelphia, PA 19104, USA.
- 14 ⁵Department of Computer and Information Science and Electrical and Systems Engineering, School of
- 15 Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA 19104, USA.
- ⁶Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- 17 ⁷Biomedical Research Imaging Center, School of Medicine, University of North Carolina at Chapel Hill,
- 18 Chapel Hill, NC 27599, USA.
- ⁸Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- ⁹Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- ¹⁰Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- 22 ¹¹Department of Statistics and Operations Research, University of North Carolina at Chapel Hill, Chapel Hill,
- 23 NC 27599, USA.
- 24
- 25 **Corresponding authors*:
- 26 Hongtu Zhu
- 27 3105C McGavran-Greenberg Hall, 135 Dauer Drive, Chapel Hill, NC 27599.
- 28 E-mail address: htzhu@email.unc.edu Phone: (919) 966-7250
- 29
- 30 Bingxin Zhao
- 31 413 Academic Research Building, 265 South 37th Street, Philadelphia, PA 19104.
- 32 E-mail address: <u>bxzhao@upenn.edu</u> Phone: (215) 898-8222

1 Abstract

2 Functional and morphological architectures of major human organs have been well 3 characterized using imaging biomarkers. Nevertheless, deciphering the causal 4 relationships between imaging biomarkers and major clinical outcomes, as well as 5 understanding the causal interplay across multiple organs, remains a formidable 6 challenge. Mendelian randomization (MR) presents a framework for inferring causality by 7 using genetic variants as instrumental variables. Here we report a systematic multi-organ 8 MR analysis between 402 imaging biomarkers and 88 clinical outcomes. We identified 488 9 genetic causal links for 62 diseases and 130 imaging biomarkers from 9 organs, tissue, or 10 systems, including the brain, heart, liver, kidney, lung, pancreas, spleen, adipose tissue, 11 and skeleton system. We prioritized crucial intra-organ causal connections, such as the 12 bidirectional genetic links between Alzheimer's disease and brain function, as well as 13 inter-organ causal effects, such as the adverse impact of heart diseases on brain health. 14 Our findings uncover the genetic causal links spanning multiple organs, offering a more 15 profound understanding of the intricate relationships between organ imaging biomarkers 16 and clinical outcomes.

17

Keywords: Brain imaging; Clinical outcomes; FinnGen; GWAS; Heart imaging; Mendelian
 randomization; MRI; Organ imaging; UK Biobank.

1 Medical images, such as magnetic resonance imaging (MRI), provide noninvasive 2 assessments of the health of major human organs, such as the brain, heart, liver, and 3 kidney. Imaging biomarkers have been widely used in clinical research and applications. 4 For example, Alzheimer's disease-related abnormalities have been consistently observed 5 in structural and functional imaging traits extracted from brain MRI, especially in the 6 hippocampal region¹. The cardiovascular MRI (CMR) provides reliable information on 7 alterations in ventricular function, cardiovascular morphology, and myocardial perfusion, all of which are closely related to cardiovascular diseases². Skeleton dual-energy X-ray 8 9 absorptiometry (DXA) helps discover novel genetic variants which influence the human 10 skeletal form and uncover a major evolutionary aspect of human anatomical change to 11 pathogenesis³. Several large-scale organ imaging datasets (on the scale of over 10,000 12 participants) have recently been made publicly available, revealing details about human organ morphology and function⁴⁻⁸. A variety of complex traits and clinical outcomes are 13 found to be associated with organ imaging biomarkers based on these well-powered 14 15 population-based studies^{9,10}. Despite these efforts, due to the inherent limitations of 16 observational data, it remains challenging to definitively determine causal relationships 17 between imaging biomarkers and clinical outcomes, as well as to fully understand the causal interconnections across multiple organs¹¹. 18

19

20 By using genetic variants as instrumental variables, Mendelian randomization (MR) can infer causality from observational data^{12,13}. With assumptions regarding genetic, 21 22 exposure, and outcome variables, MR aims to examine causal relationships between the 23 exposure and the outcome variables while controlling for unwanted confounding factors. 24 Family and population-based studies have shown that many imaging biomarkers and 25 complex diseases are strongly influenced by genetics, with hundreds of associated genetic loci being identified in large-scale genome-wide association studies (GWAS)^{8,14-29}. 26 27 Leveraging these GWAS summary-level data (summary statistics), MR methods can 28 uncover causality between imaging measurements and clinical endpoints. Several recent MR studies have examined the genetic causality of imaging biomarkers^{11,30-35}. The major 29 30 limitation of most of these MR studies has been focusing on one single organ (or imaging modality) and/or one single disease, or diseases in one single domain, such as brain 31 imaging and psychiatric disorders³⁰. It is known, however, that many diseases serve as the 32

causes and/or consequences of functional and structural changes in multiple organs of
the human body. Cross-organ analysis aids in understanding the complexity of human
physiology, subsequently enhancing our ability to diagnose, treat, and prevent a variety
of diseases. Therefore, MR analysis from a multi-organ perspective is needed to uncover
the clinical implications of imaging biomarkers in the context of the complex interplays of
organ systems.

7

8 In this paper, we performed a systematic two-sample MR analysis of multi-organ images 9 and clinical endpoints. We aggregated GWAS summary statistics from 402 multi-organ imaging biomarkers (average sample size $n \approx 35,000$) from the UK Biobank (UKB)³⁶ study 10 and 88 clinical outcomes (number of cases > 10,000) collected by the FinnGen project²⁷ 11 12 (Fig. S1 and Tables S1-S2). Specifically, we examined three major brain MRI modalities: 1) 101 regional brain volumes²¹ from brain structural MRI (sMRI); 2) 110 diffusion tensor 13 14 imaging (DTI) parameters²³ from brain diffusion MRI (dMRI); and 3) 90 functional activity 15 (amplitude³⁷) and connectivity traits from functional MRI (fMRI)²⁵. In addition, we used 82 CMR traits extracted from short-axis, long-axis, and aortic cine cardiac MRI^{38,39}. We 16 17 also evaluated 11 abdominal MRI biomarkers, which gauged the volume, fat, or iron content in seven organs and tissues⁸, as well as eight DXA imaging biomarkers that 18 measured the lengths of all long bones and the width of the hip and shoulder²⁹. The 19 20 Methods section provides more details on these multi-organ imaging biomarkers. We applied 8 MR methods⁴⁰⁻⁴⁸ to explore the bidirectional genetic causal links. The study 21 22 design is presented in **Figure 1A** and a high-level summary of our findings can be found in 23 Figure 1B.

24

25 **RESULTS**

26 Genetic causality between brain imaging and multi-organ diseases

In this section, we examined the causal relationship between brain imaging biomarkers and multi-organ diseases. At the Bonferroni significance level ($P < 5.18 \times 10^{-6}$, multiple testing adjustment for both directions), MR suggested 127 significant genetic causal effects on 58 brain imaging biomarkers from 20 diseases in 8 major categories, including mental and behavioral disorders, diseases of the nervous system, diseases of the circulatory system, cardiometabolic endpoints, interstitial lung disease endpoints,

1 diseases marked as autoimmune origin, diseases of the eye and adnexa, and diseases of 2 the genitourinary system (Fig. S2 and Table S3). Among all the diseases, heart-related 3 diseases were the most frequent (66/127) and were predominantly associated with DTI 4 parameters and a smaller number of regional brain volumes. No significant causal effects 5 were observed from heart diseases to fMRI traits. The top three heart diseases that 6 exhibited causal genetic impacts on brain structures included peripheral artery disease 7 (15/66), hypertension (14/66), and hypertensive diseases (12/66) (Figs. S2-S4). For 8 example, peripheral artery disease played a causal role in altering the white matter 9 microstructure within the anterior limb of the internal capsule (ALIC, $|\beta|$ >0.15, P < 10 3.04×10⁻⁸), the body of corpus callosum tract (BCC, $|\beta| > 0.14$, $P < 8.44 \times 10^{-7}$), and the genu of corpus callosum tract (GCC, $|\beta| > 0.13$, $P < 4.24 \times 10^{-6}$). Hypertension and hypertensive 11 12 diseases were causally associated with the superior corona radiata (SCR, $|\beta|$ > 0.07, P < 13 9.47×10^8). In addition to DTI parameters, hypertension also negatively affected the total grey matter volume ($|\beta|$ >0.02, $P < 1.26 \times 10^{-8}$) (Figs. 2C and S2-S3). In addition to heart-14 15 related diseases, several other non-neurological clinical endpoints also influenced brain 16 health. For example, negative causal effects of asthma were found on the SCR ($|\beta|$ >0.05, $P < 7.26 \times 10^{-7}$) and volume of the right inferior lateral ventricle ($|\beta| > 0.09$, $P < 8.66 \times 10^{-7}$) 17 18 (Fig. S5).

19

20 Brain disorders also causally affected the brain imaging biomarkers (49/127), with 21 dementia and Alzheimer's disease being the most common brain-related diseases (Fig. 22 **S2**). Interestingly, brain disorders were primarily associated with fMRI traits. For example, 23 Alzheimer's disease was consistently found to be causally related to decreased functional activity in the dorsal attention ($|\beta|$ >0.04, $P < 5.07 \times 10^{-8}$), frontoparietal, and secondary 24 visual network ($|\beta|$ >0.04, $P < 4.70 \times 10^{-8}$), as well as DTI parameters of the SCR ($|\beta|$ >0.03, 25 26 $P < 1.85 \times 10^{-6}$) (Figs. 2A and S6). Both functional MRI and DTI parameters have been extensively used to study Alzheimer's disease⁴⁹. Abnormalities in white matter, such as 27 those in the left SCR, as well as decreased functional connectivity in attention-related 28 networks, have been identified in patients with Alzheimer's disease^{50,51}. Similar to 29 30 Alzheimer's disease, dementia demonstrated negative causal genetic effects on 31 functional activity in multiple networks, including the cingulo-opercular, default mode, 32 dorsal attention, frontoparietal, language, posterior multimodal, and secondary visual

networks (|β|>0.12, P < 4.74×10⁻⁸) (Figs. 2B and S7). In addition, mood disorders affected
 brain volume traits, such as the left and right putamen (|β|>0.04, P < 5.64×10⁻⁷) (Fig. S8).
 More results on causal genetic links from clinical endpoints to brain imaging traits were
 summarized in Figures S3-S9.

5

6 Brain and other organ diseases may also be caused by structural or functional changes in 7 the brain. We investigated this direction by using brain imaging traits as exposure 8 variables and clinical endpoints as the outcome variables. At the Bonferroni significance 9 level ($P < 5.18 \times 10^{-6}$), we found 85 significant pairs between 22 brain imaging biomarkers 10 and 20 clinical endpoints (Fig. S10 and Table S3). Most of the significant imaging-disease 11 pairs were related to fMRI traits. Specifically, 66 of the 85 pairs were associated with fMRI 12 traits, 10 with DTI parameters, and 9 with regional brain volumes. The majority of the 13 significant findings were related to brain diseases (65/85), with a minor proportion linked to heart diseases (13/85), autoimmune diseases (4/85), COPD and related endpoints 14 15 (1/85), diseases of the eye and adnexa (1/85), and diseases of the genitourinary system 16 (1/85). For example, decreased activity in multiple functional networks was related to a higher risk of Alzheimer's disease, such as the default mode and dorsal-attention 17 networks ($|\beta| > 0.5$, $P < 5.65 \times 10^{-13}$) (Figs. 3A and S11). We also identified genetic causal 18 19 effects from DTI parameters on Alzheimer's disease, such as the BCC and SCR ($|\beta|$ >0.49, 20 $P < 6.79 \times 10^{-7}$) (Figs. 3A and S11).

21

22 Dementia exhibited a similar pattern to Alzheimer's disease, being causally influenced by 23 decreased activity in multiple networks, such as the default mode, dorsal-attention, and secondary visual network ($|\beta|$ >0.002, $P < 2.77 \times 10^{-7}$) (Fig. 3B and S12). fMRI traits, 24 25 including the functional activity of the secondary visual network and functional 26 connectivity of the default mode network, were also causally linked to other brain diseases, such as neuropsychiatric disorders ($|\beta|$ >0.09, P<8.88×10⁻¹⁶) and neurological 27 diseases ($|\beta| > 0.06$, $P < 1.72 \times 10^{-6}$) (Figs. S13 and S14). Finally, we found that brain 28 29 structural alterations may also influence other non-neurological diseases. For example, the left basal forebrain posed a negative causal effect on hypertensive diseases ($|\beta| > 0.12$, 30 $P < 8.47 \times 10^{-9}$) and hypertension ($|\beta| > 0.15$, $P < 6.19 \times 10^{-11}$). The left lingual negatively 31 affected female genital prolapse ($|\beta| > 0.75$, $P < 8.68 \times 10^{-7}$). 32

1

2 Causal genetic relationships between CMR traits and clinical outcomes

3 We first examined the causal effects from clinical endpoints to CMR measures of heart 4 structure and function. We identified 111 significant results at the Bonferroni significance 5 level ($P < 6.85 \times 10^{-6}$), covering 41 unique CMR traits of the ascending aorta (AAo), descending aorta (DAo), left atrium (LA), and left ventricle (LV). Significant causal effects 6 7 were found from 13 unique clinical endpoints in three categories: diseases of the 8 circulatory system (8/13), cardiometabolic endpoints (4/13), as well as COPD and related 9 endpoints (1/13). The majority of significant findings were related to heart-related 10 diseases, with 66 out of 111 being diseases of the circulatory system and 44 out of 111 11 being cardiometabolic endpoints (Fig. S15 and Table S4).

12

13 The most frequently observed genetic effects were related to hypertensive diseases and 14 hypertension (Figs. 4A and S16). Specifically, hypertensive diseases had negative causal 15 effects on AAo and DAo distensibility ($|\beta| > 0.10$, $P < 1.26 \times 10^{-7}$), whose genetic associations have been found in previous studies⁵²⁻⁵⁴. Hypertensive diseases also affected 16 LV and LA traits, such as the global radial strain ($|\beta|$ >0.06, P < 4.47×10⁻⁹), LA stroke 17 volume ($|\beta| > 0.07$, $P < 3.04 \times 10^{-8}$), and LV myocardial mass ($|\beta| > 0.11$, $P < 3.04 \times 10^{-15}$). 18 These findings were consistent with previous results derived from genetic association 19 20 studies^{55,56}. Hypertension exhibited a similar pattern to hypertensive diseases, having a causal impact on various AAo and DAo traits, such as DAo distensibility, along with LA and 21 22 LV traits, such as the LA minimum volume (LA_{min} volume, $|\beta| > 0.03$, $P < 7.11 \times 10^{-6}$).

23

24 In addition, angina pectoris causally influenced AAo maximum and minimum areas 25 (AAo_{max} and AAo_{min} areas, $|\beta| > 0.71$, $P < 1.44 \times 10^{-7}$). The aortic aneurysm had a positive 26 causal effect on DAo maximum and minimum areas (DAo_{max} and DAo_{min} areas, $|\beta| > 0.71$, $P < 1.63 \times 10^{-24}$) and AAo_{max} and AAo_{min} areas ($|\beta| > 0.16$, $P < 2.22 \times 10^{-6}$). These results align 27 28 with clinical observations. Atrial fibrillation and flutter mainly affected LA traits, such as 29 the LA ejection fraction ($|\beta|$ >0.07, P < 5.88×10⁻⁸), LA maximum volume (LA_{max} volume, $|\beta| > 0.07$, $P < 1.62 \times 10^{-6}$), and LA_{min} volume ($|\beta| > 0.08$, $P < 8.26 \times 10^{-8}$). Atrial fibrillation is 30 31 considered to result in a decrease in ejection fraction as well as an increase in LA volumes^{57,58}. In addition to heart-related diseases, COPD and related endpoints were 32

1 found to influence CMR traits, such as the negative effect of COPD on DAomax area 2 $(|\beta| > 0.10, P < 4.45 \times 10^{-11})$, and **Fig. S16**). Emphysema, a form of COPD distinguished by the 3 degradation of lung tissue, may contribute to the dilatation of the thoracic aorta⁵⁹. This 4 could be attributed to emphysema's involvement in the degradation of elastic fibers within the lungs, potentially triggering alterations in the aortic wall's elasticity⁶⁰. Such 5 6 changes may precipitate the dilatation or ballooning of the thoracic aorta, thereby 7 escalating the risk of both aortic aneurysm and abdominal aortic abnormalities⁵⁹. This 8 elucidates the potential biological mechanisms driving these causal relationships.

9

10 On the other hand, structural and functional irregularities of the heart may increase the 11 risk of multi-organ diseases, given that the heart pumps blood to all other organs to 12 maintain their functions⁶¹. We tested this direction by treating CMR traits as exposure 13 variables and clinical endpoints as the outcomes. After Bonferroni adjustment (P < P6.85×10⁻⁶), we found 27 significant causal pairs, 25 for heart-related diseases and 2 for 14 15 autoimmune diseases (Fig. S17 and Table S4). For example, global peak circumferential 16 strain was positively linked to heart failure and antihypertensive medication ($|\beta|$ >0.51, P $< 8.49 \times 10^{-8}$), while LV ejection fraction had a negative causal effect on these conditions 17 $(|\beta| > 0.55, P < 1.12 \times 10^{-6})$. In addition to heart-related diseases, heart structural changes 18 19 affected diseases marked as autoimmune origin. For example, right ventricular end-20 systolic volume had a negative causal effect on the autoimmune diseases defined by Finngen²⁷ ($|\beta|$ >0.18, $P < 3.10 \times 10^{-6}$) (**Figs. 4B** and **S18**). In summary, we discovered causal 21 22 relationships between CMR traits and heart-related diseases, which were typically 23 bidirectional. Additionally, we revealed the inter-organ causal relationships between the 24 heart and other organs.

25

26 Causal genetic links between abdominal imaging biomarkers and clinical outcomes

We first examined the effects of multi-organ diseases on abdominal imaging biomarkers, such as the volume or iron content of the spleen, kidney, liver, lung, and pancreas⁸. At the Bonferroni significance level ($P < 6.69 \times 10^{-5}$), we discovered 51 significant causal pairs from multi-organ diseases to abdominal imaging biomarkers, with liver imaging traits being the most impacted (26/51). Brain-related diseases were the most prevalent among all significant findings (35/51), followed by heart-related diseases (7/51), rheumatoid

endpoints (4/51), diseases of the eye and adnexa (3/51), and autoimmune diseases (2/51)
(Fig. S19 and Table S5). These findings were in line with ongoing research on the interplay
between the brain and abdominal organs, such as the brain-gut connection⁶²⁻⁶⁴, brainkidney connection^{65,66}, and brain-liver connection⁶⁷.

5

6 Alzheimer's disease and dementia were consistently found to be causally linked with 7 various abdominal imaging biomarkers, such as the percent liver fat ($|\beta|$ > 0.37, P < 4.96×10⁻⁶), liver volume ($|\beta|$ >0.03, P < 5.88×10⁻⁵), and adipose tissue measurement 8 9 $(|\beta|>0.06, P < 3.13 \times 10^{-5})$. In addition to Alzheimer's disease and dementia, there were 10 multiple other brain-related diseases that may affect abdominal organs, including mental 11 and behavioral disorders due to alcohol and psychoactive substance use, as well as sleep 12 apnoea. For example, sleep apnoea influenced several abdominal traits, such as the liver 13 volume ($|\beta| > 0.11$, $P < 2.80 \times 10^{-5}$) and kidney volume ($|\beta| > 0.23$, $P < 2.57 \times 10^{-6}$). Sleep apnea can lead to renal damage caused by ischemic stress, hemodynamic changes, or 14 15 intermediary conditions such as hypertension, which can result in early chronic kidney disease^{68,69}. Multiple heart-related diseases also genetically impacted abdominal organs. 16 17 For example, heart failure and antihypertensive medication can lead to larger spleen volume ($|\beta|$ > 0.004, P < 2.66×10⁻⁶). It has been found that heart splenic enlargement often 18 results from blood stasis and right heart disease is often accompanied by splenomegaly⁷⁰. 19 20 Atherosclerosis was causally linked to the pancreas iron content, which was also supported by clinical evidence^{71,72}. 21

22

23 In addition to brain and heart-related diseases, we also observed causal effects from other diseases, such as autoimmune diseases on spleen volume and liver iron content. 24 25 The spleen, as the largest immune organ in the body, can become enlarged because of 26 various rheumatic and immune system diseases, such as systemic lupus erythematosus, Felty's syndrome, sarcoidosis, and autoimmune hepatitis⁷³⁻⁷⁶. Liver iron content causally 27 related to both autoimmune and rheumatological diseases ($|\beta| > 0.10$, $P < 3.02 \times 10^{-5}$). It 28 29 has been found that excessive deposition of iron ions exists in the affected tissues of 30 autoimmune diseases, such as brain tissues of multiple sclerosis patients and synovial fluid of patients with rheumatoid arthritis⁷⁷. Disorders of the choroid and retina, as well 31 32 as the eye and adnexa diseases, were also found to be causally linked to liver iron content

1 ($|\beta| > 0.10$, $P < 6.48 \times 10^{-5}$, Figs. 5A and S20). Metal tends to accumulate in human ocular 2 tissues, particularly in the choroid and retinal pigment epithelium⁷⁸.

3

4 Next, we tested the opposite direction that abdominal imaging biomarkers being the 5 exposure variables and multi-organ diseases being the outcomes. At the Bonferroni 6 significance level ($P < 6.69 \times 10^{-5}$), we identified 55 significant pairs, with heart-related 7 diseases being the most prevalent (34/55), followed by brain-related diseases (11/55), 8 diseases marked as autoimmune origin (2/55), diseases of the eye and adnexa (5/55), and 9 diseases of the genitourinary system (3/55) (Fig. S21 and Table S5). For example, pancreas 10 fat causally affected the deep vein thrombosis of lower extremities and pulmonary embolism ($|\beta|$ > 0.38, P < 1.04×10⁻¹²). A reduction in pancreatic fat content may directly 11 12 improve cellular function and insulin secretion rate, affecting triglyceride levels and blood flow⁷⁹. 13

14

15 Larger liver, spleen, and kidney volumes were all causally linked to heart-related diseases 16 (Fig. 5B and S22). Specifically, a larger liver volume was causally linked to hypertensive diseases and hypertension ($|\beta|$ >0.13, $P < 1.19 \times 10^{-10}$); a larger kidney volume was causally 17 related to a higher risk of stroke ($|\beta|$ > 0.25, P < 3.33×10⁻⁵); and a larger spleen volume 18 19 had causal effects on various heart-related diseases, including coronary angioplasty $(|\beta|>0.14, P < 4.94\times10^{-7})$, coronary atherosclerosis $(|\beta|>0.07, P < 6.94\times10^{-10})$, and 20 peripheral artery diseases ($|\beta| > 0.21$, $P < 4.98 \times 10^{-5}$). In nephrotic syndrome, platelet over-21 22 activation and the use of diuretics and glucocorticoids can aggravate hypercoagulability. 23 Therefore, kidney diseases, especially nephrotic syndrome, are prone to thrombotic and embolic complications, which can lead to stroke⁸⁰⁻⁸². For brain-related disorders, we 24 25 detected causal effects from liver volume to alcohol use disorder, as well as mental and 26 behavioral disorders due to alcohol and psychoactive substance use. In addition, percent 27 liver fat had causal links with Alzheimer's disease, dementia, and psychiatric diseases. 28 Previous studies have reported that non-alcoholic fatty liver disease contributes to 29 neurological conditions like cognitive impairment and memory loss via insulin resistance and inflammation, along with excessive cytokine secretion⁸³⁻⁸⁶. In summary, we found 30 31 that brain-related disorders result in alterations in abdominal organs. Furthermore, 32 bidirectional relationships are observed in both neurodegenerative and psychiatric

1 disorders. On the other hand, multiple abdominal organs are causally linked to heart-

2 related diseases.

3

4 Causal genetic links between skeleton DXA traits and clinical outcomes

We first identified the causal effects of multiple organ diseases on DXA-derived skeleton 5 6 traits³. At the Bonferroni significance level ($P < 3.39 \times 10^{-5}$), we found strong evidence that 7 multi-organ diseases affected the human skeleton health, where heart-related diseases 8 (6/12) and diseases of the nervous system (4/12) were the majority, as well as rheumatic 9 disease (1/12) and diseases of the genitourinary system (1/12) (Fig. S23 and Table S6). 10 Carpal tunnel syndrome ($|\beta|$ >0.0007, P < 6.25×10⁻⁸) and sleep approve ($|\beta|$ >0.001, P < 6.35×10⁻⁸) were causally related to higher average forearm length. Carpal tunnel 11 12 syndrome is when the median nerve (nerve from the forearm to the palm of the hand) 13 becomes pressed or squeezed, which affects the wrist-to-forearm ratio^{87,88}. It has been 14 observed that oral appliance therapy⁸⁹, which is an effective treatment of sleep apnea, is 15 associated with skeletal changes⁹⁰. Furthermore, the nerve, nerve root, and plexus 16 disorders were causally linked with higher average tibia length ($|\beta| > 0.001$, $P < 2.78 \times 10^{-10}$ 17 ⁵), which was consistent with the previous finding that a specific type of plexus disorder, lumbosacral plexus disorder, is associated with lower leg⁹¹. Heart-related diseases also 18 had causal effects on several DXA traits. For example, coronary heart disease had a 19 negative causal effect on the average tibia length ($|\beta|$ >0.0002, P < 2.50×10⁻⁵) and a 20 positive causal effect on the hip width ($|\beta|$ > 0.0004, P < 1.68×10⁻⁵). Additionally, 21 22 gonarthrosis affected the average tibia length ($|\beta|$ >0.0005, P < 1.69×10⁻⁵) (**Figs. 6A** and 23 S24).

24

25 The skeletal system serves as the foundational support for the human body, and therefore, skeletal abnormalities may potentially contribute to risk of multi-organ diseases. We 26 27 identified 17 causal pairs at the Bonferroni significance level ($P < 3.39 \times 10^{-5}$). More than half (10/17) of these results were related to the heart, and the rest were rheumatic 28 29 disease (3/17), diseases of the eye and adnexa (2/17), interstitial lung diseases (1/17), and diseases of the genitourinary system (1/17) (Fig. S23 and Table S6). Average tibia length 30 was causally linked to coxarthrosis ($|\beta|$ >30.03, $P < 3.11 \times 10^{-9}$), gonarthrosis ($|\beta|$ >19.39, P31 < 3.18×10^{-7}), and other rheumatological endpoints ($|\beta|$ >13.12, P < 2.74×10⁻⁵). It has been 32

found that the leg length discrepancy could lead to lower limb biomechanics, such as 1 2 gonarthrosis, coxarthrosis, and other lower limb symptoms^{92,93}. Torso length causally affected heart-related issues, such as coronary angioplasty ($|\beta|$ > 38.85, P < 9.45×10⁻⁵), 3 4 coronary atherosclerosis ($|\beta|>22.94$, $P < 1.22 \times 10^{-5}$), hard cardiovascular diseases 5 $(|\beta| > 18.12, P < 1.30 \times 10^{-5})$, and ischemic heart diseases $(|\beta| > 30.99, P < 1.33 \times 10^{-5})$. Previous studies examining the relationship between skeletal length and heart diseases 6 7 have primarily focused on leg length or overall body height, generally reporting negative 8 associations^{94,95}. Consistent with these associations, we found that a long torso can lead 9 to a higher risk of heart disease. We also observed higher average tibia length to be 10 causally linked to a lower risk of hypertension ($|\beta|$ >6.46, $P < 1.27 \times 10^{-7}$), which was in line with previous findings⁹⁶ (Figs. 6B and S25). In conclusion, we found that rheumatoid 11 12 endpoints (such as gonarthrosis) and diseases of the nervous system (such as nerve, nerve 13 root, and plexus disorders) had a significant impact on bone health. Conversely, skeletal traits, like torso length, demonstrated a causal link with heart diseases. 14

15

16 Discussion

17 Observational studies have established numerous links between various imaging-derived 18 phenotypes and clinical outcomes. However, these associations are frequently influenced 19 by residual confounding, complicating the accurate inference of causal effect sizes ⁹⁷. MR 20 allows for the inference of causal relationships between exposure and outcome variables. 21 MR leverages the natural and random assortment of genetic variants during meiosis, 22 making these variants an ideal choice as instrumental variables to discern causal effects. 23 In the present study, we evaluated the causal relationship between 402 multi-organ imaging biomarkers and 88 clinical outcomes through bidirectional MR. To avoid the issue 24 25 of sample overlap⁹⁸, which may bias the causal effect and has sometimes been overlooked 26 in many current MR-based studies, we used a two-sample MR design and sourced our 27 imaging and clinical data from different large-scale cohorts.

28

It is widely understood that diseases often affect more than just one part of the human
body, given the interdependent nature of our organ systems for overall body function.
The brain and heart are particularly important among all organs, as the brain manages a
range of functions, including reactions, emotions, vision, memory, and cognition^{99,100}

1 while the heart serves as the engine of the body, pumping life-sustaining blood through 2 a network of arteries and veins to supply other organs with the oxygen and nutrients they 3 need. Dysfunctions in various organs can potentially have adverse effects on the brain 4 and heart. Similarly, abnormalities within the brain and heart can result in dysfunction in 5 other parts of the body. Our results support the presence of robust bidirectional interactions between the brain and heart with other organs. In addition to the 6 7 connections to the brain and heart, we also discovered many other causal relationships 8 for other organs. The interaction plot across different organ systems can be found in 9 Figure 1B. Below we provide more detailed discussions of these specific findings.

10

11 Intra-brain causal connections.

12 Variations in brain structure and function were closely linked with brain disorders, with 13 parts of these relationships appearing to be bidirectional. We consistently found causal 14 links between brain imaging biomarkers and multiple psychiatric disorders or neurological 15 diseases, such as Alzheimer's disease, dementia, mood disorder, and sleep apnea. For 16 example, Alzheimer's disease and dementia had bidirectional causal links with fMRI traits 17 and DTI parameters. Previous studies have consistently shown that resting fMRI connectivity patterns are altered in patients with Alzheimer's disease^{101,102}, especially in 18 brain regions involved in memory and cognitive function^{103,104}. 19

20

21 Brain-heart causal connections.

22 While association studies have been investigating the brain-heart interaction^{39,105}, the 23 causal genetic links within these heart-brain systems remain largely unexplored. We 24 discovered causal connections from several heart-related diseases such as hypertension, 25 hypertensive diseases, heart failure, and peripheral artery disease to DTI parameters in 26 white matter tracts such as the SCR, ALIC, BCC, GCC, the splenium of corpus callosum, and 27 the retrolenticular part of the internal capsule (RLIC). Additionally, these diseases were also linked to regional brain volumes, such as grey matter and left amygdala. 28 Hypertension can lead to damage of the blood vessels in the brain¹⁰⁶, which can in turn 29 lead to a reduction in the volume of grey matter in certain brain regions¹⁰⁷. This may result 30 31 in cognitive impairment and an increased risk of developing dementia. Therefore, 32 effective management of hypertension through lifestyle changes and medication can help

reduce the risk of these negative effects on the brain. On the other hand, alterations in brain structure, such as deformations in the left ventral DC and left basal forebrain, were found to contribute to heart-related diseases like hypertension. Similarly, changes in the left superior temporal region were linked to heart failure. These could be attributed to the brain's essential function in controlling blood pressure via a sophisticated network that involves multiple regions and pathways^{108,109}.

7

8 *Bidirectional connections between the brain and abdominal organs.*

9 Brain abnormalities affected multiple abdominal organs and the skeletal system. For 10 example, Alzheimer's disease and dementia causally affected the percent liver fat, and neurological diseases (defined by FinnGen²⁷) had a positive causal effect on lung volume. 11 12 It has been found that neurological diseases, such as multiple sclerosis, Parkinson's 13 disease, amyotrophic lateral sclerosis, and Huntington's disease, can cause respiratory 14 muscle weakness^{110,111}, which can affect lung volume and function. We also found sleep 15 apnoea may lead to larger spleen and kidney volume. This may be due to the increased 16 workload on the spleen to filter blood and remove damaged red blood cells. Additionally, 17 the low oxygen levels associated with sleep apnea can lead to an increase in the number 18 of red blood cells in the body, which can also contribute to splenomegaly and a change in 19 kidney volume. Sleep apnea was causally associated with increased pancreas iron content, 20 potentially due to the decreased oxygen levels that accompany sleep apnea, resulting in 21 increased iron absorption in the body. The excess iron in the pancreas can lead to oxidative stress and inflammation^{112,113}, which can contribute to the development of 22 23 pancreatic damage and dysfunction¹¹⁴⁻¹¹⁶.

24

25 In addition to the aforementioned neurological diseases, we also discovered that mental 26 and behavioral disorders attributed to alcohol can lead to an increase in percent liver fat. 27 It has been found that people with alcohol use disorder are more likely to develop alcoholic fatty liver disease¹¹⁷. Besides brain-related diseases, brain structural 28 29 alternations could also lead to a higher risk of diseases of other organs. For example, right 30 postcentral was causally linked to COPD. Some studies have suggested that chronic stress 31 and anxiety, which are associated with changes in brain structure, may contribute to the development or worsening of respiratory conditions such as COPD^{118,119}. 32

1

2 On the other hand, brain imaging biomarkers or disorders were causally affected by 3 several diseases of other organs or systems. A high percent liver fat resulted in a lower risk of Alzheimer's disease and dementia. Previous studies^{120,121} have reported 4 associations between the two and our results aligned with the most recent study¹²². More 5 work is needed to understand the underlying pathophysiological mechanism. Brain 6 7 imaging biomarkers were affected by multi-organ diseases, but some of them may affect 8 the brain indirectly, such as through mediating effects of anxiety and depression. For 9 example, diseases of the genitourinary system (ovarian cyst and menorrhagia) causally 10 affected brain structural features. Ovarian cysts can cause hormonal imbalances due to the production of hormones by the cysts themselves¹²³. These hormonal imbalances can 11 12 cause a range of symptoms, such as mood swings, anxiety, and depression¹²⁴, which can 13 affect brain function and emotional regulation. Diseases of the eye and adnexa 14 (conjunctivitis) had genetic causal effects on functional connectivity traits. Conjunctivitis 15 can be caused by a viral or bacterial infection, which can potentially lead to cause systemic inflammation in the body¹²⁵. Systemic inflammation has been linked to changes in brain 16 17 function and structure and may affect brain fMRI traits^{126,127}.

18

19 In addition, asthma influenced regional brain volumes. One prevalent way in which 20 asthma impacts the brain is via the emotional and psychological stress associated with 21 managing a chronic illness. Anxiety, stress, and depression, often faced by individuals with 22 asthma, can induce alterations in brain structure. Previous studies have shown that 23 individuals with asthma may have reduced cognitive function, including impaired memory and attention, and changes in brain activity patterns during cognitive tasks^{128,129}. Last but 24 25 not least, autoimmune diseases (defined by FinnGen²⁷) affected brain imaging biomarkers, 26 such as DTI parameters of the RLIC and SCR. Multiple sclerosis is an autoimmune disease that affects the central nervous system, and the damage to the myelin sheath that 27 surrounds axons can occur in various regions of the brain^{130,131}, including the internal 28 29 capsule. The damage can cause disruptions in the neural connections passing through the 30 anterior limb, leading to symptoms such as weakness, spasticity, and difficulty with 31 balance and coordination. In some rare autoimmune diseases, such as neuromyelitis optica¹³² and autoimmune encephalitis, inflammation and damage can occur in the brain. 32

The resulting neurological symptoms can vary depending on the severity and location of the damage^{133,134}. Furthermore, autoimmune diseases that cause systemic inflammation, such as rheumatoid arthritis and lupus, which can potentially affect the brain¹³⁵ and white matter tracts^{136,137}. Chronic inflammation can lead to changes in the microstructure of white matter tracts, which can result in alterations in neural connectivity and function^{138,139}.

7

8 Intra-heart causal connections.

9 Bidirectional causal relationships were identified between heart-related diseases and 10 CMR traits. Hypertension and hypertensive diseases were found to causally influence 11 several CMR traits across various heart chambers and aorta regions. Conversely, 12 variations in CMR traits were observed to potentially lead to heart diseases. These 13 findings are in accordance with existing clinical evidence. For example, hypertension can cause the LA to enlarge, a condition known as left atrial hypertrophy^{140,141}. This 14 15 enlargement can lead to several complications, including atrial fibrillation, heart failure, 16 and stroke¹⁴². As for atrial fibrillation, the electrical signals that control the heartbeat 17 become chaotic, causing the heart to beat irregularly and often too fast. Over time, the 18 constant irregularity of the heartbeat can also cause the LA to enlarge and weaken¹⁴³.

19

20 Bidirectional connections between the heart and abdominal organs.

21 Heart diseases and various multi-organ imaging biomarkers were causally related. For 22 instance, heart failure was found to cause an increase in spleen volume. When the heart 23 is not able to pump blood effectively, it can cause an increase in the pressure from the veins to the spleen. This increased pressure can cause the spleen to enlarge, a condition 24 known as splenomegaly¹⁴⁴. In addition, the backup of blood in the liver that can occur 25 26 with heart failure can also contribute to the development of splenomegaly. Larger spleen 27 volume can conversely lead to heart failure. An enlarged spleen can increase the workload 28 on the heart, leading to further worsening of heart failure symptoms.

29

Pancreas was also found to have a causal effect on the heart. For example, excess
 pancreas fat was found to cause a higher risk of developing deep vein thrombosis of lower
 extremities and pulmonary embolism. Pancreatic steatosis is a condition where fat

accumulates in the pancreas. This is associated with a number of metabolic abnormalities,
 including insulin resistance and inflammation, which can contribute to the development
 of cardiovascular disease^{145,146}. The inflammatory and procoagulant effects of excess
 pancreatic fat could potentially contribute to an increased risk of deep vein thrombosis.
 The heart and lungs are closely connected and work together as part of the cardiovascular

6 The heart and lungs are closely connected and work together as part of the cardiovascular 7 system. The lungs are responsible for taking in oxygen from the air we breathe and 8 transferring it into the bloodstream, while the heart pumps the oxygen-rich blood 9 throughout the body to nourish cells and tissues. We found strong evidence of causal links 10 from COPD and CMR traits of DAo. The degradation of elastic fibers through proteolysis 11 is a characteristic of emphysema¹⁴⁷, which can potentially lead to the enlargement of the 12 thoracic aorta.

13

Spleen, as the largest immune organ, is closely related with diseases marked as autoimmune origin. We found strong evidence showing the genetic causal relationship between spleen volume and autoimmune diseases (defined by Finngen²⁷), such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. It has been reported that autoimmune diseases can affect the spleen. For instance, conditions like lupus or rheumatoid arthritis can lead to splenomegaly, a condition often triggered by inflammation or the accumulation of abnormal immune cells in the spleen^{148,149}.

21

22 <u>Skeleton DXA traits.</u>

23 We also found genetic causal links between skeleton DXA traits and multiple organ 24 diseases. Skeleton traits were causally affected by diseases of the nervous system, 25 rheumatic disease, as well as nerve, nerve root and plexus disorders. Heart diseases may 26 also impact the skeletal system by influencing bone health. It has been observed that 27 individuals with heart disease, especially those with heart failure, have an increased risk of osteoporosis and bone fractures^{149,150}. This may be due to a variety of factors. For 28 29 example, some medications used to treat heart diseases, such as diuretics and steroids, can also increase the risk of osteoporosis¹⁵¹. Additionally, individuals with heart disease 30 31 may have reduced mobility and physical activity, which can lead to decreased bone density and strength¹⁵². Skeleton problems could also inversely contribute to numerous 32

organ diseases, with heart conditions being the most prevalent in our analysis. A long
torso may lead to a high risk of coronary heart disease. We also noted that a higher
average tibia length was causally associated with a lower risk of hypertension, a finding
that aligns with clinical observations⁹⁶.

5

6 *Limitations and conclusions.*

7 Our study has several limitations. First, we collected GWAS summary statistics from 8 publicly available databases, meaning that we were not able to evaluate the impact of 9 unobserved confounders (such as population stratification) on our results. Second, one 10 common limitation of most existing MR methods is that they require several model 11 assumptions, and thus may suffer from model misspecifications and data heterogeneity 12 issues when integrating data from different data resources¹⁵³. We have systematically 13 applied quality control measures and conducted sensitivity analyses in our study. Future research implementing more advanced MR methods may relax some of the model 14 15 assumptions the current MR methods have made^{154,155}. Furthermore, MR studies are 16 designed to examine the effects of lifetime exposure factors on outcomes, not 17 interventions within a specified period. As such, our findings may have different 18 interpretations from rigorous results obtained from randomized controlled trials. 19 Therefore, any clinical interventions based on these MR findings should be undertaken 20 with caution.

21

In conclusion, we used two-sample bidirectional MR analyses to comprehensively explore the multi-organ causal connections between 88 clinical outcomes and 402 image-derived phenotypes of various organ systems. Our results revealed robust genetic evidence supporting causal connections within and across multiple organs. This will aid in unraveling complex pathogenic mechanisms and will contribute to the early prediction and prevention of multi-organ diseases from a whole body perspective.

28

29 METHODS

30 Methods are available in the *Methods* section.

31 Note: One supplementary pdf file and one supplementary table zip file are available.

1 ACKNOWLEDGEMENTS

2 The study has been partially supported by funding from the Wharton Dean's Research 3 Fund and Analytics at Wharton, as well as start-up funds from Purdue Statistics 4 Department. This research has been conducted using summary-level data from the UK 5 Biobank study and FinnGen research project. We would like to thank the individuals who 6 represented themselves in the UK Biobank and FinnGen studies for their participation and the research teams for their efforts in collecting, processing, and disseminating these 7 8 datasets. We would like to thank the research computing groups at the University of 9 North Carolina at Chapel Hill, Purdue University, and the Wharton School of the University 10 of Pennsylvania for providing computational resources and support that have contributed 11 to these research results. 12 13 AUTHOR CONTRIBUTIONS J.S. and B.Z. designed the study. J.S., R.Z., C.C., B.L., Z. F., X.Y., Y.Y, X.W., and Y.L. analyzed 14 15 the data. B.X., T.L., and H.Z. provided feedback on the results. J.S. and B.Z. wrote the 16 manuscript with feedback from all authors. 17 18 CORRESPONDENCE AND REQUESTS FOR MATERIALS should be addressed to H.Z. and B.Z. 19 20 **COMPETING FINANCIAL INTERESTS** 21 The authors declare no competing financial interests. 22 23 REFERENCES 24 1. Buckner, R.L., et al. Molecular, structural, and functional characterization of 25 Alzheimer's disease: evidence for a relationship between default activity, 26 amyloid, and memory. Journal of neuroscience 25, 7709-7717 (2005). 27 2. Pennell, D.J., et al. Clinical indications for cardiovascular magnetic resonance 28 (CMR): Consensus Panel report. European heart journal 25, 1940-1965 (2004). 29 3. Kun, E., et al. The genetic architecture of the human skeletal form. bioRxiv, 30 2023.2001. 2003.521284 (2023).

Petersen, S.E., *et al.* UK Biobank's cardiovascular magnetic resonance protocol.
 Journal of cardiovascular magnetic resonance 18, 1-7 (2015).

1	5.	Littlejohns, T.J., Sudlow, C., Allen, N.E. & Collins, R. UK Biobank: opportunities for
2		cardiovascular research. European heart journal 40, 1158-1166 (2019).
3	6.	Miller, K.L., et al. Multimodal population brain imaging in the UK Biobank
4		prospective epidemiological study. Nature Neuroscience 19, 1523-1536 (2016).
5	7.	Thompson, P.M., et al. ENIGMA and global neuroscience: A decade of large-scale
6		studies of the brain in health and disease across more than 40 countries.
7		Translational psychiatry 10 , 1-28 (2020).
8	8.	Liu, Y., et al. Genetic architecture of 11 organ traits derived from abdominal MRI
9		using deep learning. <i>Elife</i> 10, e65554 (2021).
10	9.	Smith, S.M. & Nichols, T.E. Statistical challenges in "big data" human
11		neuroimaging. Neuron 97, 263-268 (2018).
12	10.	Tian, Y.E., et al. Heterogeneous aging across multiple organ systems and
13		prediction of chronic disease and mortality. Nature Medicine, 1-11 (2023).
14	11.	Taschler, B., Smith, S.M. & Nichols, T.E. Causal inference on neuroimaging data
15		with Mendelian randomisation. Neurolmage, 119385 (2022).
16	12.	Sanderson, E., et al. Mendelian randomization. Nature Reviews Methods Primers
17		2 , 1-21 (2022).
18	13.	Pingault, JB., et al. Using genetic data to strengthen causal inference in
19		observational research. Nature Reviews Genetics 19, 566-580 (2018).
20	14.	Aung, N., et al. Genome-wide analysis of left ventricular image-derived
21		phenotypes identifies fourteen loci associated with cardiac morphogenesis and
22		heart failure development. Circulation 140, 1318-1330 (2019).
23	15.	Córdova-Palomera, A., et al. Cardiac Imaging of Aortic Valve Area From 34 287
24		UK Biobank Participants Reveals Novel Genetic Associations and Shared Genetic
25		Comorbidity With Multiple Disease Phenotypes. Circulation: Genomic and
26		Precision Medicine 13 , e003014 (2020).
27	16.	Meyer, H.V., et al. Genetic and functional insights into the fractal structure of the
28		heart. <i>Nature 584,</i> 589-594 (2020).
29	17.	Pirruccello, J.P., et al. Analysis of cardiac magnetic resonance imaging in 36,000
30		individuals yields genetic insights into dilated cardiomyopathy. Nature
31		communications 11 , 1-10 (2020).

1	18.	Pirruccello, J.P., et al. Genetic Analysis of Right Heart Structure and Function in
2		40,000 People. <i>bioRxiv</i> (2021).
3	19.	Thanaj, M., et al. Genetic and environmental determinants of diastolic heart
4		function. <i>medRxiv</i> (2021).
5	20.	Elliott, L.T., et al. Genome-wide association studies of brain imaging phenotypes
6		in UK Biobank. <i>Nature 562,</i> 210-216 (2018).
7	21.	Zhao, B., et al. Genome-wide association analysis of 19,629 individuals identifies
8		variants influencing regional brain volumes and refines their genetic co-
9		architecture with cognitive and mental health traits. Nature genetics 51, 1637-
10		1644 (2019).
11	22.	Smith, S.M., et al. An expanded set of genome-wide association studies of brain
12		imaging phenotypes in UK Biobank. <i>Nature neuroscience</i> 24 , 737-745 (2021).
13	23.	Zhao, B., et al. Common genetic variation influencing human white matter
14		microstructure. Science 372, eabf3736 (2021).
15	24.	Grasby, K.L., et al. The genetic architecture of the human cerebral cortex. Science
16		367 , eaay6690 (2020).
17	25.	Zhao, B., et al. Genetic influences on the intrinsic and extrinsic functional
18		organizations of the cerebral cortex. <i>medRxiv</i> , 2021.2007. 2027.21261187
19		(2021).
20	26.	Watanabe, K., et al. A global overview of pleiotropy and genetic architecture in
21		complex traits. <i>Nature genetics</i> 51 , 1339-1348 (2019).
22	27.	Kurki, M.I., et al. FinnGen: Unique genetic insights from combining isolated
23		population and national health register data. medRxiv (2022).
24	28.	Flynn, B.I., et al. Deep learning based phenotyping of medical images improves
25		power for gene discovery of complex disease. <i>medRxiv</i> , 2023.2003.
26		2007.23286909 (2023).
27	29.	Kun, E., et al. The genetic architecture of the human skeletal form. bioRxiv
28		(2023).
29	30.	Guo, J., et al. Mendelian randomization analyses support causal relationships
30		between brain imaging-derived phenotypes and risk of psychiatric disorders.
31		Nature Neuroscience 25 , 1519-1527 (2022).

1	31.	Chen, X., et al. Kidney damage causally affects the brain cortical structure: a
2		Mendelian randomization study. EBioMedicine 72, 103592 (2021).
3	32.	Williams, J.A., et al. Inflammation and brain structure in schizophrenia and other
4		neuropsychiatric disorders: a Mendelian randomization study. JAMA psychiatry
5		79 , 498-507 (2022).
6	33.	Topiwala, A., et al. Associations between moderate alcohol consumption, brain
7		iron, and cognition in UK Biobank participants: observational and mendelian
8		randomization analyses. PLoS medicine 19, e1004039 (2022).
9	34.	Holmes, M.V., et al. Mendelian randomization of blood lipids for coronary heart
10		disease. <i>European heart journal</i> 36 , 539-550 (2015).
11	35.	Lamina, C. & Kronenberg, F. Estimation of the required lipoprotein (a)-lowering
12		therapeutic effect size for reduction in coronary heart disease outcomes: a
13		Mendelian randomization analysis. JAMA cardiology 4, 575-579 (2019).
14	36.	Sudlow, C., et al. UK biobank: an open access resource for identifying the causes
15		of a wide range of complex diseases of middle and old age. PLoS medicine 12,
16		e1001779 (2015).
17	37.	Bijsterbosch, J., et al. Investigations into within-and between-subject resting-
18		state amplitude variations. Neuroimage 159 , 57-69 (2017).
19	38.	Bai, W., et al. A population-based phenome-wide association study of cardiac
20		and aortic structure and function. Nature Medicine 26, 1654-1662 (2020).
21	39.	Zhao, B., et al. Heart-brain connections: phenotypic and genetic insights from
22		magnetic resonance images. Science, just-accepted (2023).
23	40.	Bowden, J., et al. A framework for the investigation of pleiotropy in two-sample
24		summary data Mendelian randomization. Statistics in medicine 36, 1783-1802
25		(2017).
26	41.	Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian randomization analysis
27		with multiple genetic variants using summarized data. Genetic epidemiology 37,
28		658-665 (2013).
29	42.	Bowden, J., et al. Improving the accuracy of two-sample summary-data
30		Mendelian randomization: moving beyond the NOME assumption. Int J
31		Epidemiol 48 , 728-742 (2019).

1	43.	Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
2		instruments: effect estimation and bias detection through Egger regression.
3		International journal of epidemiology 44 , 512-525 (2015).
4	44.	Hartwig, F.P., Davey Smith, G. & Bowden, J. Robust inference in summary data
5		Mendelian randomization via the zero modal pleiotropy assumption.
6		International journal of epidemiology 46 , 1985-1998 (2017).
7	45.	Bowden, J., Davey Smith, G., Haycock, P.C. & Burgess, S. Consistent estimation in
8		Mendelian randomization with some invalid instruments using a weighted
9		median estimator. Genetic epidemiology 40 , 304-314 (2016).
10	46.	Ye, T., Shao, J. & Kang, H. Debiased inverse-variance weighted estimator in two-
11		sample summary-data Mendelian randomization. The Annals of statistics 49,
12		2079-2100 (2021).
13	47.	Zhao, Q., Wang, J., Hemani, G., Bowden, J. & Small, D.S. Statistical inference in
14		two-sample summary-data Mendelian randomization using robust adjusted
15		profile score. The Annals of Statistics 48, 1742-1769 (2020).
16	48.	Wang, J., et al. Causal inference for heritable phenotypic risk factors using
17		heterogeneous genetic instruments. <i>PLoS genetics</i> 17 , e1009575 (2021).
18	49.	Oishi, K., Mielke, M.M., Albert, M., Lyketsos, C.G. & Mori, S. DTI analyses and
19		clinical applications in Alzheimer's disease. J Alzheimers Dis 26 Suppl 3, 287-296
20		(2011).
21	50.	Yin, RH., et al. Multimodal voxel-based meta-analysis of white matter
22		abnormalities in Alzheimer's disease. Journal of Alzheimer's Disease 47, 495-507
23		(2015).
24	51.	Li, R., et al. Attention-related networks in Alzheimer's disease: A resting
25		functional MRI study. Human brain mapping 33 , 1076-1088 (2012).
26	52.	Stratos, C., Stefanadis, C., Kallikazaros, I., Boudoulas, H. & Toutouzas, P.
27		Ascending aorta distensibility abnormalities in hypertensive patients and
28		response to nifedipine administration. The American journal of medicine 93, 505-
29		512 (1992).
30	53.	Asmar, R., et al. Aortic distensibility in normotensive, untreated and treated
31		hypertensive patients. Blood pressure 4, 48-54 (1995).

1	54.	Nabati, M., Namazi, S.S., Yazdani, J. & Sharif Nia, H. Relation between aortic
2		stiffness index and distensibility with age in hypertensive patients. International
3		journal of general medicine, 297-303 (2020).
4	55.	Lembo, M., et al. Advanced imaging tools for evaluating cardiac morphological
5		and functional impairment in hypertensive disease. Journal of Hypertension 40,
6		4-14 (2022).
7	56.	Di Palo, K.E. & Barone, N.J. Hypertension and heart failure: prevention, targets,
8		and treatment. Heart failure clinics 16, 99-106 (2020).
9	57.	Gopinathannair, R., et al. Managing atrial fibrillation in patients with heart failure
10		and reduced ejection fraction: a scientific statement from the American Heart
11		Association. Circulation: Arrhythmia and Electrophysiology 14, e000078 (2021).
12	58.	Packer, M. Do most patients with obesity or type 2 diabetes, and atrial
13		fibrillation, also have undiagnosed heart failure? A critical conceptual framework
14		for understanding mechanisms and improving diagnosis and treatment.
15		European journal of heart failure 22 , 214-227 (2020).
16	59.	Fujikura, K., et al. Aortic enlargement in chronic obstructive pulmonary disease
17		(COPD) and emphysema: The Multi-Ethnic Study of Atherosclerosis (MESA) COPD
18		study. Int J Cardiol 331 , 214-220 (2021).
19	60.	Maclay, J.D., et al. Systemic elastin degradation in chronic obstructive pulmonary
20		disease. <i>Thorax</i> 67 , 606-612 (2012).
21	61.	Berman, M.N., Tupper, C. & Bhardwaj, A. Physiology, Left Ventricular Function.
22		(2019).
23	62.	Kim, DY. & Camilleri, M. Serotonin: a mediator of the brain–gut connection.
24		Official journal of the American College of Gastroenterology ACG 95 , 2698-2709
25		(2000).
26	63.	Jones, M., Dilley, J., Drossman, D. & Crowell, M. Brain–gut connections in
27		functional GI disorders: anatomic and physiologic relationships.
28		Neurogastroenterology & Motility 18 , 91-103 (2006).
29	64.	Keefer, L., et al. A Rome working team report on brain-gut behavior therapies for
30		disorders of gut-brain interaction. Gastroenterology 162, 300-315 (2022).
31	65.	Xie, Z., Tong, S., Chu, X., Feng, T. & Geng, M. Chronic kidney disease and
32		cognitive impairment: The kidney-brain axis. <i>Kidney Diseases</i> 8 , 275-285 (2022).

1	66.	de Donato, A., Buonincontri, V., Borriello, G., Martinelli, G. & Mone, P. The
2		dopamine system: insights between kidney and brain. Kidney and Blood Pressure
3		Research 47 , 493-505 (2022).
4	67.	McCracken, C., et al. Multi-organ imaging demonstrates the heart-brain-liver axis
5		in UK Biobank participants. Nature Communications 13, 7839 (2022).
6	68.	Voulgaris, A., Marrone, O., Bonsignore, M.R. & Steiropoulos, P. Chronic kidney
7		disease in patients with obstructive sleep apnea. A narrative review. Sleep
8		Medicine Reviews 47 , 74-89 (2019).
9	69.	Sim, J.J., Rasgon, S.A. & Derose, S.F. Managing sleep apnoea in kidney diseases.
10		Nephrology 15, 146-152 (2010).
11	70.	O'Reilly, R.A. Splenomegaly in 2,505 patients in a large university medical center
12		from 1913 to 1995. 1913 to 1962: 2,056 patients. Western journal of medicine
13		169 , 78 (1998).
14	71.	Vinchi, F., et al. Atherosclerosis is aggravated by iron overload and ameliorated
15		by dietary and pharmacological iron restriction. European heart journal 41, 2681-
16		2695 (2020).
17	72.	Kempf, T. & Wollert, K.C. Iron and atherosclerosis: too much of a good thing can
18		be bad. European Heart Journal (2020).
19	73.	Balint, G.P. & Balint, P.V. Felty's syndrome. Best practice & research clinical
20		rheumatology 18 , 631-645 (2004).
21	74.	Blendis, L., Ansell, I., Jones, K.L., Hamilton, E. & Williams, R. Liver in Felty's
22		syndrome. <i>Br Med J</i> 1, 131-135 (1970).
23	75.	Kataria, Y.P. & Whitcomb, M.E. Splenomegaly in sarcoidosis. Archives of Internal
24		Medicine 140 , 35-37 (1980).
25	76.	Candia, L., Marquez, J. & Espinoza, L.R. Autoimmune hepatitis and pregnancy: a
26		rheumatologist's dilemma. in Seminars in arthritis and rheumatism, Vol. 35 49-56
27		(Elsevier, 2005).
28	77.	Wang, Z., et al. Iron drives T helper cell pathogenicity by promoting RNA-binding
29		protein PCBP1-mediated proinflammatory cytokine production. Immunity 49, 80-
30		92. e87 (2018).
31	78.	Erie, J.C., et al. Heavy metal concentrations in human eyes. American journal of
32		ophthalmology 139 , 888-893 (2005).

1	79.	Honka, H., et al. The effects of bariatric surgery on pancreatic lipid metabolism
2		and blood flow. The Journal of Clinical Endocrinology & Metabolism 100, 2015-
3		2023 (2015).
4	80.	Huang, JA., Lin, CH., Chang, YT., Lee, CT. & Wu, MJ. Nephrotic syndrome is
5		associated with increased risk of ischemic stroke. Journal of Stroke and
6		Cerebrovascular Diseases 28 , 104322 (2019).
7	81.	Gigante, A., et al. Nephrotic syndrome and stroke. International Journal of
8		Immunopathology and Pharmacology 26 , 769-772 (2013).
9	82.	Roy, C., et al. Ischemic stroke of possible embolic etiology associated with
10		nephrotic syndrome. <i>Kidney International Reports</i> 2 , 988-994 (2017).
11	83.	Cheon, S.Y. & Song, J. Novel insights into non-alcoholic fatty liver disease and
12		dementia: insulin resistance, hyperammonemia, gut dysbiosis, vascular
13		impairment, and inflammation. Cell & Bioscience 12, 1-14 (2022).
14	84.	Rodrigo, R., et al. Hyperammonemia induces neuroinflammation that
15		contributes to cognitive impairment in rats with hepatic encephalopathy.
16		Gastroenterology 139 , 675-684 (2010).
17	85.	Rose, C.F., et al. Hepatic encephalopathy: Novel insights into classification,
18		pathophysiology and therapy. Journal of hepatology 73 , 1526-1547 (2020).
19	86.	Kong, S.H., Park, Y.J., Lee, JY., Cho, N.H. & Moon, M.K. Insulin resistance is
20		associated with cognitive decline among older Koreans with normal baseline
21		cognitive function: a prospective community-based cohort study. Scientific
22		reports 8 , 650 (2018).
23	87.	Hobson-Webb, L.D., Massey, J.M., Juel, V.C. & Sanders, D.B. The
24		ultrasonographic wrist-to-forearm median nerve area ratio in carpal tunnel
25		syndrome. <i>Clinical neurophysiology</i> 119 , 1353-1357 (2008).
26	88.	Paluch, Ł., Pietruski, P., Walecki, J. & Noszczyk, B.H. Wrist to forearm ratio as a
27		median nerve shear wave elastography test in carpal tunnel syndrome diagnosis.
28		Journal of Plastic, Reconstructive & Aesthetic Surgery 71 , 1146-1152 (2018).
29	89.	Gotsopoulos, H., Chen, C., Qian, J. & Cistulli, P.A. Oral appliance therapy
30		improves symptoms in obstructive sleep apnea: a randomized, controlled trial.
31		American journal of respiratory and critical care medicine 166 , 743-748 (2002).

1	90.	Araie, T., Okuno, K., Minagi, H.O. & Sakai, T. Dental and skeletal changes
2		associated with long-term oral appliance use for obstructive sleep apnea: a
3		systematic review and meta-analysis. Sleep Medicine Reviews 41, 161-172
4		(2018).
5	91.	Sander, J.E. & Sharp, F.R. Lumbosacral plexus neuritis. Neurology 31 , 470-473
6		(1981).
7	92.	Khamis, S. & Carmeli, E. A new concept for measuring leg length discrepancy.
8		Journal of orthopaedics 14 , 276-280 (2017).
9	93.	Raczkowski, J.W., Daniszewska, B. & Zolynski, K. Functional scoliosis caused by
10		leg length discrepancy. Archives of Medical Science 6, 393-398 (2010).
11	94.	Nelson, C.P., et al. Genetically determined height and coronary artery disease.
12		New England Journal of Medicine 372 , 1608-1618 (2015).
13	95.	Schmidt, M., Bøtker, H.E., Pedersen, L. & Sørensen, H.T. Adult height and risk of
14		ischemic heart disease, atrial fibrillation, stroke, venous thromboembolism, and
15		premature death: a population based 36-year follow-up study. European journal
16		of epidemiology 29 , 111-118 (2014).
17	96.	Yin, F., Spurgeon, H.A., Rakusan, K., Weisfeldt, M.L. & Lakatta, E.G. Use of tibial
18		length to quantify cardiac hypertrophy: application in the aging rat. American
19		Journal of Physiology-Heart and Circulatory Physiology 243 , H941-H947 (1982).
20	97.	Walker, V.M., Zheng, J., Gaunt, T.R. & Smith, G.D. Phenotypic Causal Inference
21		Using Genome-Wide Association Study Data: Mendelian Randomization and
22		Beyond. Annu Rev Biomed Data Sci 5, 1-17 (2022).
23	98.	Burgess, S., Davies, N.M. & Thompson, S.G. Bias due to participant overlap in
24		two-sample Mendelian randomization. Genetic epidemiology 40, 597-608 (2016).
25	99.	Berridge, K.C. & Kringelbach, M.L. Pleasure systems in the brain. Neuron 86, 646-
26		664 (2015).
27	100.	Bressler, S.L. & Menon, V. Large-scale brain networks in cognition: emerging
28		methods and principles. Trends Cogn Sci 14, 277-290 (2010).
29	101.	Wang, K., et al. Altered functional connectivity in early Alzheimer's disease: A
30		resting-state fMRI study. <i>Human brain mapping</i> 28 , 967-978 (2007).

1	102.	Sorg, C., et al. Selective changes of resting-state networks in individuals at risk
2		for Alzheimer's disease. Proceedings of the National Academy of Sciences 104,
3		18760-18765 (2007).
4	103.	Ranasinghe, K.G., et al. Regional functional connectivity predicts distinct
5		cognitive impairments in Alzheimer's disease spectrum. NeuroImage: Clinical 5,
6		385-395 (2014).
7	104.	Pini, L., et al. A low-dimensional cognitive-network space in Alzheimer's disease
8		and frontotemporal dementia. Alzheimer's Research & Therapy 14, 199 (2022).
9	105.	Liu, W., et al. Brain-heart communication in health and diseases. Brain Research
10		Bulletin (2022).
11	106.	Walker, K.A., Power, M.C. & Gottesman, R.F. Defining the relationship between
12		hypertension, cognitive decline, and dementia: a review. Current hypertension
13		reports 19 , 1-16 (2017).
14	107.	Zhang, H., et al. Reduced regional gray matter volume in patients with chronic
15		obstructive pulmonary disease: a voxel-based morphometry study. American
16		Journal of Neuroradiology 34 , 334-339 (2013).
17	108.	do Carmo, J.M., et al. Role of the brain melanocortins in blood pressure
18		regulation. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1863,
19		2508-2514 (2017).
20	109.	Goriely, A., et al. Mechanics of the brain: perspectives, challenges, and
21		opportunities. Biomechanics and modeling in mechanobiology 14, 931-965
22		(2015).
23	110.	Polkey, M.I., Lyall, R.A., Moxham, J. & Leigh, P.N. Respiratory aspects of
24		neurological disease. Journal of Neurology, Neurosurgery & Psychiatry 66, 5-15
25		(1999).
26	111.	Pollock, R.D., Rafferty, G.F., Moxham, J. & Kalra, L. Respiratory muscle strength
27		and training in stroke and neurology: a systematic review. International Journal
28		of Stroke 8 , 124-130 (2013).
29	112.	Tian, C., Zhao, J., Xiong, Q., Yu, H. & Du, H. Secondary iron overload induces
30		chronic pancreatitis and ferroptosis of acinar cells in mice. International Journal
31		of Molecular Medicine 51 , 1-13 (2023).

1	113.	Galaris, D., Barbouti, A. & Pantopoulos, K. Iron homeostasis and oxidative stress:
2		An intimate relationship. Biochimica et Biophysica Acta (BBA)-Molecular Cell
3		Research 1866 , 118535 (2019).
4	114.	Robles, L., Vaziri, N.D. & Ichii, H. Role of oxidative stress in the pathogenesis of
5		pancreatitis: effect of antioxidant therapy. Pancreatic disorders & therapy 3, 112
6		(2013).
7	115.	Armstrong, J., et al. Oxidative stress in acute pancreatitis: lost in translation?
8		Free radical research 47 , 917-933 (2013).
9	116.	Pérez, S., Pereda, J., Sabater, L. & Sastre, J. Redox signaling in acute pancreatitis.
10		<i>Redox biology</i> 5 , 1-14 (2015).
11	117.	Kushner, T. & Cafardi, J. Chronic liver disease and COVID-19: alcohol use
12		disorder/alcohol-associated liver disease, nonalcoholic fatty liver
13		disease/nonalcoholic steatohepatitis, autoimmune liver disease, and
14		compensated cirrhosis. Clinical Liver Disease 15, 195 (2020).
15	118.	Grant, I., Heaton, R.K., McSweeney, A.J., Adams, K.M. & Timms, R.M. Brain
16		dysfunction in COPD. <i>Chest</i> 77 , 308-309 (1980).
17	119.	Spilling, C.A., et al. Factors affecting brain structure in smoking-related diseases:
18		Chronic Obstructive Pulmonary Disease (COPD) and coronary artery disease.
19		<i>PLoS One</i> 16 , e0259375 (2021).
20	120.	Kim, G.A., et al. Association between non-alcoholic fatty liver disease and the risk
21		of dementia: a nationwide cohort study. Liver international 42, 1027-1036
22		(2022).
23	121.	Kim, DG., et al. Non-alcoholic fatty liver disease induces signs of Alzheimer's
24		disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD
25		model. Journal of neuroinflammation 13, 1-18 (2016).
26	122.	Wang, L., Sang, B. & Zheng, Z. Risk of dementia or cognitive impairment in non-
27		alcoholic fatty liver disease: A systematic review and meta-analysis. Frontiers in
28		Aging Neuroscience 14 (2022).
29	123.	Mobeen, S. & Apostol, R. Ovarian cyst. (2020).
30	124.	Padda, J., et al. Depression and its effect on the menstrual cycle. Cureus
31		13 (2021).

1	125.	Azari, A.A. & Barney, N.P. Conjunctivitis: a systematic review of diagnosis and
2		treatment. <i>Jama</i> 310 , 1721-1730 (2013).
3	126.	Sankowski, R., Mader, S. & Valdés-Ferrer, S.I. Systemic inflammation and the
4		brain: novel roles of genetic, molecular, and environmental cues as drivers of
5		neurodegeneration. Frontiers in cellular neuroscience 9, 28 (2015).
6	127.	Elwood, E., Lim, Z., Naveed, H. & Galea, I. The effect of systemic inflammation on
7		human brain barrier function. Brain, behavior, and immunity 62, 35-40 (2017).
8	128.	Rhyou, HI. & Nam, YH. Association between cognitive function and asthma in
9		adults. Annals of Allergy, Asthma & Immunology 126 , 69-74 (2021).
10	129.	Ray, M., Sano, M., Wisnivesky, J.P., Wolf, M.S. & Federman, A.D. Asthma control
11		and cognitive function in a cohort of elderly adults. Journal of the American
12		Geriatrics Society 63 , 684-691 (2015).
13	130.	Alvarez, J.I., Cayrol, R. & Prat, A. Disruption of central nervous system barriers in
14		multiple sclerosis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of
15		Disease 1812 , 252-264 (2011).
16	131.	Krupp, L.B., et al. International Pediatric Multiple Sclerosis Study Group criteria
17		for pediatric multiple sclerosis and immune-mediated central nervous system
18		demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis
19		Journal 19 , 1261-1267 (2013).
20	132.	Huda, S., et al. Neuromyelitis optica spectrum disorders. Clinical Medicine 19,
21		169 (2019).
22	133.	Kim, W., Kim, SH., Huh, SY. & Kim, H.J. Brain abnormalities in neuromyelitis
23		optica spectrum disorder. Multiple sclerosis international 2012(2012).
24	134.	Lancaster, E. The diagnosis and treatment of autoimmune encephalitis. Journal
25		of Clinical Neurology 12 , 1-13 (2016).
26	135.	Wartolowska, K., et al. Structural changes of the brain in rheumatoid arthritis.
27		Arthritis & Rheumatism 64 , 371-379 (2012).
28	136.	Kozora, E. & Filley, C.M. Cognitive dysfunction and white matter abnormalities in
29		systemic lupus erythematosus. Journal of the International Neuropsychological
30		Society 17 , 385-392 (2011).
31	137.	Appenzeller, S., et al. Longitudinal analysis of gray and white matter loss in
32		patients with systemic lupus erythematosus. <i>Neuroimage</i> 34 , 694-701 (2007).

1	138.	Rosenberg, G.A. Inflammation and white matter damage in vascular cognitive
2		impairment. <i>Stroke</i> 40 , S20-S23 (2009).
3	139.	Raj, D., et al. Increased white matter inflammation in aging-and Alzheimer's
4		disease brain. Frontiers in molecular neuroscience 10 , 206 (2017).
5	140.	Gerdts, E., et al. Correlates of left atrial size in hypertensive patients with left
6		ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in
7		Hypertension (LIFE) Study. Hypertension 39 , 739-743 (2002).
8	141.	Eshoo, S., Ross, D.L. & Thomas, L. Impact of mild hypertension on left atrial size
9		and function. Circulation: Cardiovascular Imaging 2, 93-99 (2009).
10	142.	Sanfilippo, A.J., et al. Atrial enlargement as a consequence of atrial fibrillation. A
11		prospective echocardiographic study. Circulation 82, 792-797 (1990).
12	143.	van de Vegte, Y.J., Siland, J.E., Rienstra, M. & van der Harst, P. Atrial fibrillation
13		and left atrial size and function: a Mendelian randomization study. Scientific
14		reports 11 , 8431 (2021).
15	144.	Hiraiwa, H., et al. Clinical significance of spleen size in patients with heart failure.
16		<i>European Heart Journal</i> 42 , ehab724. 0756 (2021).
17	145.	Ormazabal, V., et al. Association between insulin resistance and the
18		development of cardiovascular disease. Cardiovascular diabetology 17, 1-14
19		(2018).
20	146.	Shah, A., Mehta, N. & Reilly, M.P. Adipose inflammation, insulin resistance, and
21		cardiovascular disease. Journal of Parenteral and Enteral Nutrition 32 , 638-644
22		(2008).
23	147.	Thurlbeck, W.M. & Müller, N. Emphysema: definition, imaging, and
24		quantification. AJR. American journal of roentgenology 163, 1017-1025 (1994).
25	148.	Fernández-García, V., González-Ramos, S., Martín-Sanz, P., Castrillo, A. & Boscá,
26		L. Contribution of extramedullary hematopoiesis to atherosclerosis. The spleen
27		as a neglected hub of inflammatory cells. <i>Frontiers in Immunology</i> 11 , 586527
28		(2020).
29	149.	Suttorp, M. & Classen, C.F. Splenomegaly in children and adolescents. Frontiers
30		in pediatrics, 693 (2021).
31	150.	Lampropoulos, C.E., Papaioannou, I. & D'cruz, D.P. Osteoporosis—a risk factor
32		for cardiovascular disease? <i>Nature Reviews Rheumatology</i> 8 , 587-598 (2012).

1	151.	Gaines, J.M., et al. Older men's knowledge of osteoporosis and the prevalence of
2		risk factors. Journal of Clinical Densitometry 13 , 204-209 (2010).
3	152.	Whalen, R., Carter, D. & Steele, C. Influence of physical activity on the regulation
4		of bone density. <i>Journal of biomechanics</i> 21 , 825-837 (1988).
5	153.	Zhao, Q., Wang, J., Spiller, W., Bowden, J. & Small, D.S. Two-sample instrumental
6		variable analyses using heterogeneous samples. Statistical Science 34, 317-333
7		(2019).
8	154.	Cui, R., et al. Improving fine-mapping by modeling infinitesimal effects. bioRxiv,
9		2022.2010. 2021.513123 (2022).
10	155.	Xue, H., Shen, X. & Pan, W. Causal Inference in Transcriptome-Wide Association
11		Studies with Invalid Instruments and GWAS Summary Data. Journal of the
12		American Statistical Association, 1-27 (2023).
13	156.	Tseng, W.Y., Su, M.Y. & Tseng, Y.H. Introduction to Cardiovascular Magnetic
14		Resonance: Technical Principles and Clinical Applications. Acta Cardiol Sin 32,
15		129-144 (2016).
16	157.	Pennell, D.J. Cardiovascular magnetic resonance. Circulation 121, 692-705
17		(2010).
18	158.	Bai, W., et al. Automated cardiovascular magnetic resonance image analysis with
19		fully convolutional networks. Journal of Cardiovascular Magnetic Resonance 20,
20		1-12 (2018).
21	159.	Bai, W., et al. Recurrent neural networks for aortic image sequence
22		segmentation with sparse annotations. International conference on medical
23		image computing and computer-assisted intervention, 586-594 (2018).
24	160.	Miller, K.L., et al. Multimodal population brain imaging in the UK Biobank
25		prospective epidemiological study. Nat Neurosci 19, 1523-1536 (2016).
26	161.	Zhao, B., et al. Heritability of regional brain volumes in large-scale neuroimaging
27		and genetic studies. Cerebral Cortex 29, 2904-2914 (2019).
28	162.	Zhao, B., et al. Large-scale GWAS reveals genetic architecture of brain white
29		matter microstructure and genetic overlap with cognitive and mental health
30		traits (n= 17,706). <i>Molecular psychiatry</i> 26 , 3943-3955 (2021).
31	163.	Avants, B.B., et al. A reproducible evaluation of ANTs similarity metric

1	164.	Jahanshad, N., et al. Multi-site genetic analysis of diffusion images and voxelwise
2		heritability analysis: A pilot project of the ENIGMA–DTI working group.
3		Neuroimage 81 , 455-469 (2013).
4	165.	Kochunov, P., et al. Multi-site study of additive genetic effects on fractional
5		anisotropy of cerebral white matter: comparing meta and megaanalytical
6		approaches for data pooling. Neuroimage 95 , 136-150 (2014).
7	166.	Glasser, M.F., et al. A multi-modal parcellation of human cerebral cortex. Nature
8		536 , 171-178 (2016).
9	167.	Ji, J.L., et al. Mapping the human brain's cortical-subcortical functional network
10		organization. Neuroimage 185, 35-57 (2019).
11	168.	Bowden, J., et al. Improving the accuracy of two-sample summary-data
12		Mendelian randomization: moving beyond the NOME assumption. International

- 13 *journal of epidemiology* **48**, 728-742 (2019).
- 14

15 METHODS

16 Multi-organ imaging biomarkers.

17 The imaging data were sourced from the UK Biobank (UKB) study, which enrolled 18 approximately 500,000 individuals aged between 40 and 69 from 2006 to 2010 19 (https://www.ukbiobank.ac.uk/). These multi-organ imaging data were collected from 20 the ongoing UKB imaging study project (https://www.ukbiobank.ac.uk/explore-your-21 participation/contribute-further/imaging-study), which aims to collect brain, heart, and 22 abdomen scans from 100,000 participants. Ethical approval for the UKB study was 23 secured from the North West Multicentre Research Ethics Committee (approval number: 24 11/NW/0382).

25

Studies of brain and heart diseases usually rely on magnetic resonance imaging (MRI) scans, which are well-established clinical endophenotypes. Cardiovascular magnetic resonance imaging (CMR) is a set of MRI techniques that are designed to assess ventricular function, cardiovascular morphology, myocardial perfusion, and other cardiac functional and structural features^{156,157}. They have been frequently used to reveal heartrelated issues clinically. The CMR traits used in the paper were originally generated from the raw short-axis, long-axis, and aortic cine images using the state-of-the-art heart

imaging segmentation and feature representation framework^{38,158,159}. We divided the 1 2 generated 82 CMR traits into 6 categories. The first two are aortic sections, namely 3 ascending aorta (AAo) and descending aorta (DAo), which serve as the main 'pipe' in 4 supplying blood to the entire body. The other four are the global measures of 4 cardiac 5 chambers, including the left ventricle (LV), right ventricle (RV), left atrium (LA), and right atrium (RA), which altogether manage the heartbeat and blood flow. There are also some 6 7 other traits, such as regional phenotypes of the left ventricle myocardial-wall thickness 8 and strain (Table S1). The summary-level GWAS data of these 82 CMR traits were 9 obtained from Zhao, et al. ³⁹.

10

Brain MRI provides detailed information about brain structure and function¹⁶⁰, such as 11 12 abnormal growth, healthy aging, white matter diseases, structural issues, and functional 13 abnormalities. In this paper, the summary-level GWAS data were collected from recent multi-modal image genetic studies, including regional brain volumes from structural 14 15 MRI^{21,161} (sMRI), diffusion tensor imaging (DTI) parameters from diffusion MRI^{23,162} (dMRI), and functional activity (that is, amplitude³⁷) and functional connectivity phenotypes from 16 17 resting functional MRI²⁵ (resting fMRI). In sMRI, we used ANTs¹⁶³ to generate regional brain volumes for cortical and subcortical regions and global brain volume measures. In 18 dMRI, we used the ENIGMA-DTI pipelines^{164,165} to generate tract-averaged parameters 19 20 for fractional anisotropy, mean diffusivity, axial diffusivity, radial diffusivity, and mode of anisotropy in major white matter tracts and across the whole brain. For resting fMRI, we 21 22 extracted phenotypes from brain parcellation-based analysis. We used the Glasser360 23 atlas¹⁶⁶, which divided the cerebral cortex into 360 regions in 12 functional networks¹⁶⁷. We considered 90 network-level resting fMRI phenotypes that evaluated interactions and 24 25 spontaneous neural activity at rest.

26

The 11 imaging biomarkers from abdominal MRI were derived by Liu., et al⁸ using deep learning methods in terms of volume, fat, and iron in several organs and tissues, such as the liver, spleen, kidney, lung, pancreas, and adipose tissue. Skeleton DXA traits, including all long bone lengths as well as hip and shoulder width, were derived by Kun., et al³ using deep learning methods on whole-body dual-energy X-ray absorptiometry (DXA) images.

All eight skeleton traits have been controlled for height. The heritability of the above
 imaging biomarkers can be found in **Supplementary Note**.

3

4 FinnGen clinical endpoints.

5 We used 88 clinical endpoints collected by the FinnGen project, which were selected from the R7 release and with more than 10,000 cases for most of the clinical endpoints 6 7 (https://www.finngen.fi/en/access results). As for some important diseases, such as 8 Alzheimer's disease, we set the cutoff of the number of cases to be 6,000. The 88 clinical 9 endpoints covered diseases from various categories, namely, mental and behavioral 10 disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the 11 genitourinary system, diseases of the circulatory systems, cardiometabolic endpoints, 12 diseases marked as autoimmune origin, rheuma endpoints, interstitial lung diseases, 13 COPD and related endpoints, as well as some unclassified endpoints. The definations can be found at https://risteys.finregistry.fi/. The FinnGen data used in our study was 14 15 obtained from separate cohorts than those supplying imaging traits, which were derived 16 from the UKB study, thus ensuring there was no sample overlap. Detailed information of 17 these 88 clinical variables can be found in Table S2.

18

19 Mendelian randomization analysis.

20 We examined the genetic causal relationships between the 402 imaging traits (101 brain 21 regional volume traits, 110 brain DTI parameters, 90 network-level fMRI phenotypes, 82 22 CMR traits, 11 abdominal traits, and 8 skeleton DXA traits) and 88 clinical endpoints. Prior 23 to conducting the Mendelian randomization (MR) analysis, we conducted standard preprocessing and quality control procedures. First, we selected genetic variants based 24 on a significance threshold of 5×10^{-8} in the exposure GWAS data. To ensure the 25 26 independence of the genetic variants used in MR, we implemented LD clumping with a window size of 10,000 and an r² threshold of 0.01, using the 1000 Genomes European 27 28 ancestry data as a reference panel. We used the TwoSampleMR package 29 (https://mrcieu.github.io/TwoSampleMR/) for harmonization, which enabled us to 30 accurately align alleles between the selected variants in the exposure and the reported 31 effect on the outcome.

1 We assessed the performance of 8 MR methods, which included Inverse variance 2 weighted (fixed effect), Inverse variance weighted (multiplicative random effect), MR-3 Egger, Simple Median, Weighted Median, Weighted Mode, DIVW, GRAPPLE, and MR-RAPS^{40,41,43-48,168}, where MR Egger was used as the pleiotropy test. To ensure the reliability 4 of our results, we implemented several quality control procedures. We excluded causal 5 estimates that relied on fewer than 6 genetic variants, as a larger number of genetic 6 variants increases the statistical power of MR analysis^{46,47}. We retained causal pairs that 7 8 were significant in at least two out of the eight methods. We also screened for pleiotropy 9 by using the MR-Egger intercept, the most used method for testing the pleiotropy 10 assumption. If a causal estimate failed the MR-Egger intercept test, we required that it 11 have significant results in at least one of the robust MR methods, such as Weighted 12 Median, Weighted Model, MR-RAPS, or GRAPPLE. Out of 488 significant findings, 81 13 causal estimates failed the MR-Egger intercept test. However, when we interpreted the results, we focused on the ones that passed the MR-Egger intercept test. 14

15

16 Code availability

17 We made use of publicly available software and tools. Our analysis code will be made

- 18 freely available at Zenodo.
- 19

20 Data availability

21 We used summary-level GWAS data in this study, which can be obtained from the

22 FinnGen project (https://www.finngen.fi/en/access_results), BIG-KP (https://bigkp.org/),

Heart-KP (<u>https://heartkp.org/</u>), and project-specific resources detailed in Liu., et al⁸ and

24 Kun., et al³. Our multi-organ MR results can be explored at <u>https://mr4mo.org/</u>.



1 Fig. 1 Overview of study design and findings.

2 (A). An overview of our multi-organ imaging genetic study for 88 clinical outcomes. Multi-3 modal brain imaging traits, cardiac imaging traits, abdominal imaging traits, as well as 4 skeleton DXA imaging traits were used to investigate the relationship between 88 clinical 5 endpoints. We covered a full spectrum of brain imaging modalities, including structural 6 MRI, diffusion MRI, and resting fMRI. Cardiac imaging data were composed of short-axis, 7 long-axis, and aortic cine images. Volume, iron content, and percent fat were measured 8 in 6 different abdominal organs and tissues, resulting in 11 image-derived abdominal 9 phenotypes. We have 8 skeleton imaging traits that covered long bone lengths as well as 10 hip and shoulder width. (B). A high-level summary of our bidirectional findings. IDPs, 11 imaging derived phenotypes.



Fig. 2 Selected genetic causal effects of clinical outcomes on brain imaging biomarkers. 1 2 We illustrated selected significant ($P < 5.18 \times 10^{-6}$) causal genetic links from clinical 3 endpoints (Exposure) to brain imaging biomarkers (Outcome) after adjusting for multiple testing using the Bonferroni procedure. (A). The causal effect of Alzheimer's disease on 4 5 brain imaging biomarkers. (B). The causal effect of dementia on brain imaging biomarkers. 6 (C). The causal effect of hypertension on brain imaging biomarkers. IDP Category, 7 category of imaging biomarkers; #IVs, the number of genetic variants used as instrumental variables. Different MR methods and their regression coefficients are 8 9 labeled with different colors. See Table S1 for data resources of clinical endpoints and Table S2 for data resources of imaging biomarkers. 10



1 Fig. 3 Selected genetic causal effects of brain imaging biomarkers on clinical endpoints.

We illustrated selected significant ($P < 5.18 \times 10^{-6}$) causal genetic links from brain imaging 2 3 biomarkers (Exposure) to clinical endpoints (Outcome) after adjusting for multiple testing 4 using the Bonferroni procedure. (A). The causal effect of brain imaging biomarkers on 5 Alzheimer's diseases. (B). The causal effect of brain imaging biomarkers on dementia. IDP Category, category of imaging biomarkers; #IVs, the number of genetic variants used as 6 instrumental variables. Different MR methods and their regression coefficients are 7 8 labeled with different colors. See Table S1 for data resources of clinical endpoints and 9 Table S2 for data resources of imaging biomarkers.

Exposure II	DP Categor	y Outcome	#IVs	Estim	nates	Exposure	IDP Categ	ory Outcome	#IVs	Estim	nates
COPD	AAo	Descending aorta maximum area	7			Ascending aorta maximum area	AAo	Diseases of arteries, arterioles and capillaries	47		* + + + + + +
Hypertensive diseases (excluding secondary)	AAo	Ascending aorta distensibility	111			Global peak circumferential stra	in LV	Heart failure and antihypertensive medication	10		
Hypertensive diseases (excluding secondary)	DAo	Descending aorta distensibility	111			Global peak circumferential stra	in LV	Heart failure and antihypertensive medication	10		
Hypertensive diseases (excluding secondary)	LV	Global radial strain	111			Left ventricular end diastolic volume	d- LV	Heart failure and antihypertensive medication	10	+++++++++++++++++++++++++++++++++++++++	-
Hypertensive diseases (excluding secondary)	LA	Left atrium stroke volume	111			Left ventricular myocardial mass	LV	Atrial fibrillation and flutter -	6		
Hypertensive diseases (excluding secondary)	LV	Left ventricular myocardial mass	111		++++	Left ventricular myocardial mass	LV	Hypertension	6	1	
Atrial fibrillation and flutter	LA	Left atrium ejection fraction	78	$\{ \{ i \} \} \in \mathcal{I}_{\mathcal{I}}$		Regional myocardia wall thickness segment 16	al LV	Hypertension	16	HHH	IVW (fixed)
Ischemic heart diseases	AAo	Ascending aorta minimum area	161	H		Right ventricular ejection fraction	RV	Heart failure and antihypertensive medication	12	+++**++	Median-ba
Hypertension	DAo	Descending aorta distensibility	161	-		Right ventricular end-systolic volum	e RV	Heart failure and antihypertensive medication	17	₩₩	GRAPPLE
Hypertension	LA	Left atrium minimum volume	161			Right ventricular ejection fraction	RV	Other heart diseases	12	+	
Hypertension	LV	Left ventricular myocardial mass	161			Right ventricular end-systolic volum	e RV	Autoimmune diseases	17		

Fig. 4 Selected genetic causal effects between heart imaging biomarkers and clinical endpoints.

We illustrated selected significant (*P* < 6.85×10⁻⁶) causal genetic links from (**A**) clinical endpoints (Exposure) to heart imaging biomarkers (Outcome) and (**B**) heart imaging biomarkers (Exposure) to clinical endpoints (Outcome) after adjusting for multiple testing using the Bonferroni procedure. IDP Category, category of imaging biomarkers; #IVs, the number of genetic variants used as instrumental variables. Different MR methods and their regression coefficients are labeled with different colors. See **Table S1** for data resources of clinical endpoints and **Table S2** for data resources of imaging biomarkers.

Α							В				
Exposure	IDP Catego	ory Outcome	#IVs	Estin	nates	_	Exposure I	DP Catego	ory Outcome	#IVs	Estimates
Autoimmune diseases	Spleen	Spleen volume	133		┿┿┿		Liver volume	Liver	Hypertensive diseases (excluding secondary)	10	
Autoimmune diseases	Liver	Liver iron content	133	++++++			Liver volume	Liver	Hypertension	10	
Mental and behavioral disorders due to alcoho	liver	Percent liver fat	6				Spleen volume	Spleen	Coronary angiopasty	33	
Mental and behavioral disorders due to alcoho	l Pancrea:	s Pancreas fat	6				Spleen volume	Spleen	Ischemic heart diseases	33	
Dementia, including avohilmo	Liver	Liver volume	10			_	Spleen volume	Spleen	Peripheral artery disease	33	
Mental and behaviora disorders due to psychoactive substance	al Liver use	Percent liver fat	6			_	Kidney volume	Kidney	Stroke, including SAH	10	
Alzheimer's disease, wide definition	Liver	Liver volume	27	+++++		t	Visceral adipose issue measurement	Adipose tissue	Sleep apnoea, Including avohilmo	6	
Alzheimer's disease, wide definition	Liver	Percent liver fat	27	+++++			Percent liver fat	Liver	Hard cardiovascular diseases	13	IVW (fixed)
Sleep apnoea	Kidney	Kidney volume	8				Percent liver fat	Liver	lschemic heart diseases	13	- DIVW - Median-based - Mode-based
Coronary atherosclerosis	Spleen	Spleen volume	8	+++++++++++++++++++++++++++++++++++++++			Percent liver fat	Liver	Myocardial infarction	13	GRAPPLE
lschemic heart diseases	Spleen	Spleen volume	8	- 11	+++ +++	_	Liver iron content	Liver	Disorders of lens	12	++++++++++++++++++++++++++++++++++++++
Disorders of choroid and retina	Liver	Liver iron content	22	- 11.1	+++		Liver iron content	Liver	Atrial fibrillation and flutter	12	+++++++++++++++++++++++++++++++++++++++
Finngen Rheumatologic endpoints	al Liver	Liver iron content	38				Liver iron content	Liver	Autoimmune diseases	12	+++++
			-(0.2 0	0 0.2	0.4				-0.5	0.0 0.5 1.0

Fig. 5 Selected genetic causal effects between abdominal imaging biomarkers and clinical endpoints.

We illustrated selected significant ($P < 6.69 \times 10^{-5}$) causal genetic links from (A) clinical 3 4 endpoints (Exposure) to abdominal imaging biomarkers (Outcome) and (B) abdominal 5 imaging biomarkers (Exposure) to clinical endpoints (Outcome) after adjusting for 6 multiple testing using the Bonferroni procedure. IDP Category, category of imaging 7 biomarkers; #IVs, the number of genetic variants used as instrumental variables. Different 8 MR methods and their regression coefficients are labeled with different colors. See Table 9 S1 for data resources of clinical endpoints and Table S2 for data resources of imaging 10 biomarkers.

Α				
Exposure	IDP Cate	gory Outcome	#IVs	Estimates
Carpal tunnel syndrome	Forear	m Average forearm	18	
Nerve, nerve root and plexus disorders	Tibia	Average Tibia	7	
Gonarthrosis [arthrosis of knee](FG) Tibia	Average tibia	28	
В			-0	0.001 0 0.001 0.002 0.003
Exposure II	OP Categor	y Outcome	#IVs	Estimates
Average tibia	Tibia	Hypertension	31	
Average tibia	Tibia ^{Fi}	nngen rheumatological endpoints	31	
Torso length	Torso	Coronary angiopasty	9	
Torso length	Torso	Major coronary heart disease event	9	
Torso length	Tibia	Coronary atherosclerosis	9	IVW (random IVW (rand
Torso length	Torso	Hard cardiovascular diseases	9	Micrain bus Micrain bus Mode-based Micrain bus Micrain bus Micrain bus Micrain bus Micrain bus Micrain bus
Torso length	Torso	Myocardial infarction	9	GRAPPLE
			-30	0 30 60 90

1 Fig. 6 Selected genetic causal effects between skeleton imaging biomarkers and clinical

2 endpoints.

We illustrated selected significant ($P < 3.39 \times 10^{-5}$) causal genetic links from (A) clinical 3 4 endpoints to (Exposure) to skeleton imaging biomarkers (Outcome) and (B) skeleton 5 imaging biomarkers (Exposure) to clinical endpoints (Outcome) after adjusting for 6 multiple testing using the Bonferroni procedure. IDP Category, category of imaging 7 biomarkers; #IVs, the number of genetic variants used as instrumental variables. Different 8 MR methods and their regression coefficients are labeled with different colors. See Table 9 S1 for data resources of clinical endpoints and Table S2 for data resources of imaging 10 biomarkers.